National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion). HTA ID: 20048

Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion) is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.

 

NCPE Assessment Process Ongoing
Rapid review commissioned 28/10/2020
Rapid review completed 18/12/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amikacin sulfate (Arikayce® liposomal nebuliser dispersion (ALND) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies
Full pharmacoeconomic assessment commissioned by HSE 04/01/2022
Full HTA Submission received from Applicant 01/04/2022
Current Status Full HTA submission received from Applicant